73832
document
Intranasal recombinant alfa-2b interferon treatment of naturally occurring common colds . In a double-blind , placebo-controlled study , patients with naturally occurring common colds of less than or equal to 48 h duration were randomly assigned to receive nasal sprays of recombinant alfa-2b interferon at 10 or 20 MU/day or placebo four times per day for 5 days . The 10-MU ( n = 74 ) , 20-MU ( n = 74 ) , and placebo ( n = 72 ) groups had comparable frequencies of documented rhinovirus colds ( 50 to 65 % ) and mean durations of pretreatment symptoms ( 26 to 27 h ) . The median duration of colds tended to be longer in the 20-MU group ( 10 days ) than the 10-MU group ( 8 days ) or placebo group ( 8 days ) ( P = 0.06 ) . In those with proven rhinovirus colds treated within 24 h , the median duration was significantly longer in the 20-MU group ( 9 days ) than in the placebo group ( 6 days ) . No differences favoring interferon treatment were found in respiratory symptom scores or resolution of specific symptoms . On days 5 and 7 , nasal washings from compliant subjects with proven rhinovirus colds yielded rhinoviruses more often in placebo ( 47 and 48 % , respectively ) than in interferon ( 15 and 16 % , respectively ) recipients ( P less than 0.02 ) , but no differences in new respiratory illness occurrence were observed in household contacts . Interferon recipients had significantly higher frequencies of blood in nasal mucus ( 16 to 18 % ) than did placebo recipients ( 4 % ) during treatment . Antibiotics for presumed secondary infections were given more often in the 20-MU group ( 11 % ) than in the placebo group ( 0 % ) ( P less than 0.01 ) . Nasal sprays of recombinant alfa-2b interferon were not an effective treatment for natural colds and were associated with toxicity .
73833
Intervention_Pharmacological
alfa-2b interferon
73834
Intervention_Pharmacological
recombinant alfa-2b interferon
73835
Intervention_Control
placebo
73836
Intervention_Control
placebo
73837
Intervention_Control
placebo
73838
Intervention_Control
placebo
73839
Intervention_Physical
nasal washings
73840
Intervention_Control
placebo
73841
Intervention_Pharmacological
interferon
73842
Intervention_Pharmacological
Interferon
73843
Intervention_Control
placebo
73844
Intervention_Pharmacological
Antibiotics
73845
Intervention_Control
placebo
73846
Intervention_Pharmacological
alfa-2b interferon
73847
Outcome_Physical
naturally occurring common colds
73848
Outcome_Physical
median duration of colds
73849
Outcome_Physical
median duration
73850
Outcome_Physical
respiratory symptom scores or resolution of specific symptoms
73851
Outcome_Physical
respiratory illness occurrence
73852
Outcome_Adverse-effects
in nasal mucus
73853
Outcome_Physical
Antibiotics
73854
Outcome_Physical
effective treatment for natural colds
73855
Outcome_Adverse-effects
toxicity
73856
Participant_Condition
common colds
73857
Participant_Condition
naturally occurring common colds
73858
Participant_Sample-size
74
73859
Participant_Sample-size
74
73860
Participant_Sample-size
72